PO.CTP01.02 · 进行中的临床试验
Phase I and Phase II Clinical Trials in Progress
- CT267 CT267 RPT1G治疗复发/难治性急性髓系白血病及高危骨髓增生异常综合征/肿瘤患者的1期、开放标签、多中心试验 Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes/neoplasms Dennise A. de Jesús-Díaz, Aaron Goldberg, Steve Abella, Caroline M. Robb, Michael Schelle, Gregory Crimmins
- CT268 CT268 ARV-393（一种PROTAC BCL6降解剂）作为单药治疗晚期非霍奇金淋巴瘤（NHL）患者或与glofitamab联合治疗弥漫性大B细胞淋巴瘤（DLBCL）患者的1期研究 Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) Martin Hutchings, Andrew Zelenetz, Jacob H. Christensen, Almudena Cascales Hernandez, Sarit Assouline, Luis E. Malpica Castillo, Shalin Kothari, Dipenkumar Modi, Miguel A. Canales Albendea, Damian Cubillas, Alejandro M. Garcia-Sancho, Catherine M. Diefenbach, John Kuruvilla, Paolo F. Caimi, Krish Patel, Sean Landrette, Eric Zhi, Yuanyuan Zhang, Roland Meier, Mathew J. Matasar
- CT269 CT269 一种三特异性（CD19/20/22）CAR T细胞疗法用于复发或难治性（R/R）B细胞恶性肿瘤的即时（point-of-care）生产与早期临床评估 Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies Joseph P. McGuirk, Rupal Soder, Ramesh Balusu, Nathaniel Dudley, Louisa Wirthlin, Tyce Bruns, David Akhavan, Scott J. Weir, Sunil Abhyankar
- CT270 CT270 进行中的临床试验：BCC020——一项使用二氟甲基鸟氨酸（DFMO）和AMXT-1501的剂量递增研究，随后开展DFMO联合或不联合AMXT-1501治疗神经母细胞瘤、CNS肿瘤和肉瘤的随机对照试验 Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas Giselle Saulnier Sholler, Genevieve Bergendahl, Kevin Bielamowicz, Derek Hanson, Deanna Mitchell, David Hoogstra, Arthur Berg, William Ferguson, Abigail Moore, Jacqueline Kraveka
- CT271 CT271 进行中的临床试验：BCC021——Silmitasertib（CX-4945）联合化疗治疗复发难治性实体瘤儿童和青年患者的I/II期研究 Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors Chandrika Behura, Genevieve Bergendahl, Julie Steinbrecher, Shouhao Zhou, William Ferguson, Jacqueline Kraveka, Kevin Mulieri, Sinisa Dovat, Abigail Moore, Giselle Saulnier Sholler
-
-
- CT274 CT274 在NCT03643549 IB/II期试验中，通过序贯使用硼替佐米和替莫唑胺抑制26S蛋白酶体，经放大的酪氨酸激酶受体信号转导以利用NF-kB这一机制性靶点，为复发性MGMT阴性GBM带来5个月的延长生存 Inhibiting 26S proteosome with sequential bortezomib and temozolomide garners 5 months prolonged survival in recurrent MGMT -negative GBM through amplified tyrosine kinase receptor signaling to avail NF-kB mechanistic target in NCT03643549 Phase IB/II trial Dorota Goplen, Mohummad Aminur Rahman, Surendra Kumar, Marianne H. Hannisdal, Victoria Arnesen, Andreas Waha, Leif Oltedal, Judit Haasz, Jorunn Brekke, Tora S. Solheim, Petter Brandal, Stein A. Lie, Martha Chekenya
- CT275 CT275 ALTER：一项随机II期试验，评估在HER2-low转移性三阴性乳腺癌中一线交替使用sacituzumab-govitecan与trastuzumab-deruxtecan方案对比单药sacituzumab-govitecan的疗效（NCT07151586） ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586) Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci
-
- CT277 CT277 IvoLoC试验：一项II期试验，评估ivonescimab在转移性内分泌难治性HR阳性HER2阴性或三阴性浸润性小叶癌（ILC）中的疗效 IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC) Jason Mouabbi, Paula Pohlmann, Rachel Layman, Roland Bassett, Lavinia Middleton, Bora Lim, Toni Zaayman, Krystle Nomie, Evgeny Barykin, Anastasiya Evdokimova, Mariana Chavez-MacGregor, Jennifer Litton, Sharon Giordano, Funda Meric-Bernstam
-
- CT280 CT280 一项关于基因组分类器在指导前列腺癌治疗决策中临床效用的实用性研究：对治疗选择、肿瘤学结局和治疗相关不良事件的影响（PROMPT-Bx） A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx) Brent Mabey, Lauren Lenz, Thaylon Davis, Alexander Gutin, Katherine Johansen Taber, Dale Muzzey, Jeff Jasper, Matthew Schiewer
-
-
- CT283 CT283 加压腹腔内气溶胶化疗（PIPAC）用于胰腺导管腺癌仅腹膜转移的患者 Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients with peritoneal-only metastasis from pancreatic ductal adenocarcinoma Julien T. Hohenleitner, Oliver J. Standring, Amber N. Habowski, Murtuza Hassan, Hai Huang, Matthew J. Weiss, Craig E. Devoe, Sepideh Gholami, Arvind Rishi, Daniel A. King, David A. Tuveson, Richard Whelan, Danielle K. Deperalta
- CT284 CT284 口服RAS(ON)多重三复合物抑制剂BPI-572270治疗RAS突变晚期实体瘤患者的首次人体I/II期研究 First-in-human, phase I/II study of BPI-572270, an oral RAS(ON) multi tri-complex inhibitor, in patients with RAS-mutated advanced solid tumors Zhengbo Song, Han Han, Xiang Yang, Wenmao Wu, Jing Guo, Hong Lan, Quan Zhou, Hui Chen, Weijie Li, Pengxiang Wu, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding
-
-
- CT287 CT287 中枢神经系统（CNS）穿透性、PARP1选择性抑制剂EIK1004治疗伴或不伴脑转移的晚期实体瘤患者的首次人体（FIH）1/2期剂量递增和剂量优化研究 A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study of central nervous system (CNS)-penetrant, PARP1-selective inhibitor EIK1004 in patients with advanced solid tumors with or without brain metastases Timothy A. Yap, Jian Zhang, Yanhua Xu, Sanum Chaudry, Kevin H. Eng, Yawei Zhang, Viola J. Chen, Gerald Falchook
-
-
- CT290 CT290 NTS071-101：一项评估NTS071在携带TP53 Y220C突变的晚期实体瘤患者中安全性、耐受性、药代动力学和初步疗效的1/2a期研究 NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation Qiancheng Shen, Yan Xu, Yinqun Wu, Shuhan Shen, Guoqiang Zhou
- CT291 CT291 IL-12前药KGX101的首次人体研究在晚期或转移性黑色素瘤中展现出肿瘤微环境特异性激活、有前景的抗肿瘤活性和可控的安全性特征 First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma Jun Guo, Lu Si, Lili Mao, Weidong Jiang, Haixiang Wu, Kahaerjiang Abuduwaili, Yi Zhao, Lianlian Jiang, Yutao Gao, Jiangfeng Fan, Naijun Tang
-
-
-
- CT295 CT295 CRD3874-SI（一种全身给药的第三代变构STING激动剂）治疗晚期实体瘤患者的I期试验 Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu, Olayade Babatunde, Lauren Banks, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Grace Gray, Camron Clark, Mary Louise Keohan, Robert G. Maki, Sujana Movva, Damon Reed, Kelly Schroeder, Li-Xuan Qin, Phillip Wong, Sandip Middya, Ritesh Shrivastava, Debjani Chakraborty, Rajib Ghosh, Sourav Basu, Arjun Surya, William D. Tap, Sandra P. D'Angelo
